-

A.forall Announces the Direct Commercialization of Sodium Acetate Injection 2mEq/mL

WHITE BEAR LAKE, Minn.--(BUSINESS WIRE)--Through its U.S. subsidiary, Milla Pharmaceuticals Inc., A.forall announced the direct commercialization and launch of Sodium Acetate Injection 2mEq/mL in 20mL, 50mL, and 100mL vials.

Sodium Acetate Injection, USP is indicated as a source of sodium for addition to large volume intravenous fluids to prevent or correct hyponatremia in patients with restricted or no oral intake. It is also useful as an additive for preparing specific intravenous fluid formulas when the needs of the patient cannot be met by standard electrolyte or nutrient solutions.

“We continue supplying Sodium Acetate in the U.S. throughout this time of shortage as we have been doing over the last four years, but we are now proudly addressing the shortage directly. Thanks to our own commercial organization, we are now able to provide U.S. patients with the medicines they need most in an even more efficient way.

“This important milestone represents the company’s continued investment in and increasing internal dedication to serving the U.S. marketplace, especially for products which have been or continue to be reported in shortage,” commented Erik Lazarich, A.forall’s President of U.S. Operations.

Please see link for Full Prescribing Information.

About A.forall & Milla Pharmaceuticals

At A.forall, our mission is all about Making Affordable Medicines Available To All: we develop value-added generic pharmaceuticals, solve product shortages and fill unmet medical needs so that patients can continue their treatment. At the same time, we are reducing costs to the healthcare system and increasing customer convenience for a more sustainable world.

Milla Pharmaceuticals Inc., the U.S. subsidiary of A.forall, is engaged in the development, licensing, acquisition, and commercialization of generic prescription drugs for the U.S. market, focusing on niche injectable and solution products for hospitals and clinics.

More info: About – A.forall & About - Milla Pharmaceuticals

Contacts

Erik Lazarich
(952) 449-5154
erik.lazarich@aforallpharma.com

Industry:

Milla Pharmaceuticals Inc.

Release Versions
English

Contacts

Erik Lazarich
(952) 449-5154
erik.lazarich@aforallpharma.com

Social Media Profiles
Milla Pharmaceuticals Inc.
A.forall
More News From Milla Pharmaceuticals Inc.

A.forall expands US generics portfolio

ANDERLECHT, Belgium--(BUSINESS WIRE)--A.forall is pleased to announce the acquisition of four FDA-approved injectable generics and two late-stage pipeline assets from Provepharm's US portfolio. With this acquisition, A.forall considerably extends its marketed portfolio in the US, marking a significant expansion of its US footprint and a key milestone in the company’s sharpened focus on high-quality generics worldwide. Strengthening Essential Healthcare The acquired portfolio includes four well-...

A.forall Announces First US Launch with Coveted Competitive Generic Therapy (CGT) Exclusivity of Tromethamine Injection 18GM/500mL

WHITE BEAR LAKE, Minn.--(BUSINESS WIRE)--A.forall announced through its U.S. subsidiary, Milla Pharmaceuticals Inc., that it has received Abbreviated New Drug Application (ANDA) approval by the U.S. Food and Drug Administration (FDA) for a generic version of THAM Solution Tromethamine Injection 18GM/500mL marketed by Hospira Inc, a Pfizer company. Tromethamine Injection is indicated for prevention and correction of metabolic acidosis. This marks the 6th overall ANDA approval for A.forall and an...

A.forall Announces the Launch of Their Fifth Abbreviated New Drug Application (ANDA) and Second “First Cycle” FDA Approval

MINNETONKA, Minn.--(BUSINESS WIRE)--A.forall’s U.S. subsidiary Milla Pharmaceuticals Inc. announced the launch of the group’s generic version of Precedex®, Dexmedetomidine Hydrochloride Injection 200 mcg per 50 mL and 400 mcg per 100 mL in 0.9% sodium chloride in glass bottles by its partner Sagent Pharmaceuticals. Dexmedetomidine Hydrochloride Injection is indicated for sedation of initially intubated and mechanically ventilated patients during treatment in an intensive care setting. Dexmedeto...
Back to Newsroom